What you need to know about CBD Products?

When you look at a CBD product, note the label. All dietary supplements should have back panels including an FDA disclaimer and a warning section. “Ideally, it would be preferable to have access to their third-party lab testing results too,” Brandon Beatty, an executive vice president of the U.S. Hemp Roundtable, said in an interview with Health. Third-party testing confirms that the label is accurate. For example, a 2017 study by the Journal of the American Medical Association found that 26% of the 84 CBD products tested contained lower doses than the label stated. You can check the brand’s website if you don’t see that info on the label.

You’ll also want to read the label carefully for dosing instructions and to determine whether the CBD is isolate or full-spectrum. The latter means the product may contain additional cannabinoids, which are sometimes more effective — and consequently may require a smaller dose.

Responsible manufacturers of CBD products should also include a batch number on the packaging. “This is a huge indicator as to whether they are following good manufacturing practices,” said Beatty. “There should be a way to identify this product in case it was improperly made so the company can carry out a recall.”

 

More Addiction Treatment Docs Needed for Opioid Crisis, House Panel Told

The opioid crisis and growing addiction to methamphetamine and other stimulants won’t be abated until the country trains more addiction medicine physicians, witnesses said at a House Energy & Commerce Health Subcommittee hearing.

“One of the things the opioid epidemic has laid bare is the lack of trained professionals we have to provide treatment, so we can put out all the funding dollars we want” but it won’t do any good without a trained workforce, said Michael Botticelli, executive director of the Grayken Center for Addiction at Boston Medical Center. “I think it’s really important for us to ensure that while we’re doing other activities such as integrating addiction treatment into residency training, that having a trained workforce of addiction medicine and addiction psychiatrists are critical.”

 

‘No controlled substances’ in lab tests on vape devices, MHS says

In a news release about 2:30 Tuesday afternoon, Madison Consolidated Schools announced that “preliminary lab results show no controlled substances in vaping devices to this point” in the continuing investigation into vaping devices and 14 EMS calls from the school to transport to King’s Daughters’ Hospital in a nine-day period.

“While final reports are still pending from the State Board of Health; preliminary results from the Indiana State Police Toxicology Lab were negative for any controlled substances in the vape devices sent for testing. The most recent device, which was confiscated last week, arrived at the lab on Friday, Feb. 21, 2020. Results on this device are pending,” the news release said.

On Tuesday morning, Feb. 25, the confiscated devices were transferred by law enforcement from the Indiana State Police Toxicology Lab to the Indiana State Board of Health Lab for further analysis.

“We are relieved by the news of the preliminary findings,” said Jacob McVey, School Resource Officer, and district School Safety Coordinator. “While we are still concerned at the number of students using these devices, we are relieved to know there are no controlled or illegal substances contained in any of the evidence we sent for testing. The latest device, confiscated last week, was delivered on Friday and we expect those results to be included in the final report from the state.

 

Baseball Players Can Smoke Marijuana But Can’t Be Sponsored By Cannabis Companies, MLB Says

With spring training now in full swing, Major League Baseball is further clarifying its stance on marijuana. Players can now consume cannabis without risk of discipline, the league explained in a new memo, but they can’t show up to work under the influence and—at least for now—are barred from entering into commercial arrangements with companies in the marijuana industry.

The league also says it’s also teaming with product-testing organization NSF International to analyze and certify legal, contaminant-free CBD products in order to allow teams to store them on club premises.

The announcements came in a new memorandum from MLB Deputy Commissioner Daniel R. Halem. Dated February 19, it’s an update to the MLB’s decision late last year to remove cannabis from the league’s list of banned substances.

Before the rule change, players who tested positive for THC were referred to mandatory treatment, and failure to comply carried a fine of up to $35,000. That penalty is now gone.

 

Medical Cannabis Pioneers Stake Their Claims

For medical cannabis, the winds of change are blowing. And while some parties are shoring up walls, others are building windmills. The walls, of course, are the laws prohibiting cannabis. In the United States, they’re crumbling here and there, allowing cannabis to be used medically and, in a few places, even recreationally. As the winds sweep over increasingly free expanses, the stigma hanging over cannabis begins to dissipate, and legitimate operations pop up to commercialize cannabis-derived products.

These operations, like windmills on the prairie, are signs of progress. Among the most promising operations are pharmaceutical companies specializing in drugs that interact with the endocannabinoid system. Most of these drugs are derived from phytocannabinoids (cannabinoids produced by plants) or synthetic compounds.

Ten years ago, the endocannabinoid system was an inaccessible frontier. Now, however, it is being surveyed by pharmaceutical companies that look forward to exploiting promising targets, starting with the endocannabinoid system’s main components: the two G-protein-coupled receptors known as cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R), and their natural ligands anandamide and 2-arachidonoylglycerol. In the coming decade, the endocannabinoid system’s richness will attract many pioneering drug developers. Eventually, they’ll build a distinct industry segment and churn out therapeutics for a broad range of diseases.